This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lotrich, F. E. Articles by Pollock, B. G. Search for Related Content PubMed PubMed Citation Articles by Lotrich, F. E. Articles by Pollock, B. G. Pubmed/NCBI databases Medline Plus Health Information Nuclear Scans Social Bookmarking                         What's this?

Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies

Department of Psychiatry, Western Psychiatric Institute and Clinics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Robert R. Bies

Department of Pharmaceutical Sciences, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Gwenn S. Smith

Department of Psychiatry Research, Zucker Hillside Hospital and Center for Neurosciences, North Shore-Long Island Jewish Research Institute and Health System, New York, USA.

Bruce G. Pollock

Department of Psychiatry, Western Psychiatric Institute and Clinics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Department of Pharmaceutical Sciences, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Department of Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; Rotman Research Institute, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, ON, Canada.

Pharmacodynamic differences are difficult to interpret without drug concentration data. In particular, variability in drug exposure may confound the interpretation of pharmacogenetic, therapeutic outcome, and neuroimaging studies. Inter-individual variability in concentrations can be quite high due to variable adherence and pharmacokinetics. For example, clearance may be influenced by genetics, drug interactions, age and illness. We review findings that acute responses to selective serotonin reuptake inhibitors can have a concentration–response relationship using positron emission tomography and neuroendocrine measures. We also present preliminary evidence that the concentration–response relationship for paroxetine is influenced by genotypic differences at the serotonin transporter promoter.

In large clinical studies, the accurate assessment of drug exposure can be challenging, with several techniques used to assess exposure. Population pharmacokinetics (Pop PK) is a method that is ideally suited for analysing concentration data from large trials because both patient-specific and population parameters can be determined with only a small number of plasma samples per patient. As opposed to relying on prescribed doses or a single trough level, the ability to determine more accurately exposure with Pop PK reduces the heterogeneity introduced by exposure variability. Pop PK hierarchic Bayesian approaches have been effective for characterizing anticonvulsants, antibiotics, antineoplastics and antiarrhythmics. We have recently successfully incorporated these pop PK analyses into routine assessments of elderly patients in clinical trials of selective serotonin reuptake inhibitors (SSRIs) and second generation antipsychotics. For the design and interpretation of neuroimaging, pharmacogenetic, and behavioural studies, the assessment of drug concentration exposure is therefore feasible and has potentially important ramifications.

Key Words: concentration • pharmacogenetics • neuroimaging • population pharmacokinetics

Journal of Psychopharmacology, Vol. 20, No. 4 suppl, 33-40 (2006)
DOI: 10.1177/1359786806066044


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?